The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia Major
Abstract
We examined the efficacy of long-term subcutaneous deferoxamine therapy in the prevention of iron-related cardiac disease in patients with thalassemia major who began treatment after the age of 10 years. Of 36 such patients without preexisting cardiac disease, 19 did not comply with the program of chelation therapy. Over the course of treatment (1977 to 1983) serum ferritin and aspartate aminotransferase levels fell in the compliant group, from mean values (+/- S.D.) of 4765 +/- 2610 to 2950 +/- 1850 ng per milliliter and 58.1 +/- 22 IU to 30 +/- 20 IU per liter, respectively (P less than 0.05), but rose in the noncompliant group, from 5000 +/- 2316 to 6040 +/- 2550 ng per milliliter and 56.6 +/- 20 to 90 +/- 35 IU per liter, respectively. Only one patient in the compliant group acquired cardiac disease and died of fulminant congestive heart failure. In contrast, 12 noncompliant patients acquired cardiac disease, and 7 died. In addition, the mean age of the compliant population (18.9 +/- 4.5 years) now approaches the mean age of acquisition of cardiac disease in the noncompliant group (19 +/- 4.3). These data demonstrate that compliance with treatment with deferoxamine may protect patients from cardiac disease induced by iron overload.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Approaches to Sudden Death from Coronary Heart Disease
LOWN, B., & WOLF, M. (1971) · Circulation · doi:10.1161/01.cir.44.1.130 · Cited by 1,257
Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis.
Marvin, H. M. (1964) · Archives of Internal Medicine · doi:10.1001/archinte.1964.00280120106032 · Cited by 384
Barry, M., Flynn, D. M., Letsky, E. A., & Risdon, R. A. (1974) · BMJ · doi:10.1136/bmj.2.5909.16 · Cited by 326
Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron Overload
Propper, R. D., Cooper, B., Rufo, R. R., Nienhuis, A. W., Anderson, W. F., Bunn, H. F., Rosenthal, A., & Nathan, D. G. (1977) · New England Journal of Medicine · doi:10.1056/nejm197708252970804 · Cited by 258
Self-citationSurvival and desferrioxamine in thalassaemia major.
Modell, B., Letsky, E. A., Flynn, D. M., Peto, R., & Weatherall, D. J. (1982) · BMJ · doi:10.1136/bmj.284.6322.1081 · Cited by 206
Cardiac Involvement in Cooley's Anemia
Engle, M. A. (1964) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1965.tb54070.x · Cited by 122
LONGITUDINAL STUDY OF CARDIAC FUNCTION IN THALASSEMIA MAJOR *
Ehlers, K. H., Levin, A. R., Markenson, A. L., Marcus, J. R., Klein, A. A., Hilgartner, M. W., & Engle, M. A. (1980) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1980.tb33678.x · Cited by 114
DESFERRIOXAMINE TO IMPROVE CARDIAC FUNCTION IN IRON-OVERLOADED PATIENTS WITH THALASSAEMIA MAJOR
Marcus, R. E., Davies, S., Bantock, H. M., Underwood, S. R., Walton, S. P., & Huehns, E. R. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90439-2 · Cited by 106
Early Left Ventricular Dysfunction and Chelation Therapy in Thalassemia Major
Freeman, A. P., GILES, R. W., BERDOUKAS, V. A., WALSH, W. F., CHOY, D., & MURRAY, P. C. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-99-4-450 · Cited by 84
Diseases of the Heart And Blood Vessels: Nomenclature and Criteria for Diagnosis (6th ed.)
Wareham, E. E. (1965) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(10)66788-4 · Cited by 46
Cited by
Salonen, J. T., Nyyssönen, K., Korpela, H., Tuomilehto, J., Seppänen, R., & Salonen, R. (1992) · Circulation · doi:10.1161/01.cir.86.3.803 · Cited by 1,284
Survival in Medically Treated Patients with Homozygous β-Thalassemia
Olivieri, N. F., Nathan, D. G., MacMillan, J. H., Wayne, A. S., Liu, P. P., McGee, A., Martin, M., Koren, G., & Cohen, A. R. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409013310903 · Cited by 852
Self-citationHershko, C., Weatherall, D. J., & Finch, C. (1988) · CRC Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408368809105894 · Cited by 141
Metadata
- Authors
- Wolfe, L., Olivieri, N., Sallan, D., Colan, S., Rose, V., Propper, R., Freedman, M. H., & Nathan, D. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1985-06-20
- Volume
- 312
- Issue
- 25
- Pages
- 1600-1603
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2331162460
- Cited by
- 265
- References
- 12
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia Major. https://app.cochat.ai/papers/10.1056/nejm198506203122503
- The paper
- Wolfe, L., Olivieri, N., Sallan, D., Colan, S., Rose, V., Propper, R., Freedman, M. H., & Nathan, D. G. (1985). Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia Major. New England Journal of Medicine. https://doi.org/10.1056/nejm198506203122503
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
